Sunshine Biopharma Inc.SBFMEarnings & Financial Report
Sunshine Biopharma Inc. is a clinical-stage biopharmaceutical company focused on researching, developing and commercializing innovative therapies for oncology, neurodegenerative disorders and infectious diseases. It targets unmet medical needs across global markets, with a pipeline of targeted therapeutic candidates designed to improve patient treatment outcomes.
Revenue
$9.4M
Gross Profit
$3.4M
Operating Profit
$-2.1M
Net Profit
$-1.8M
Gross Margin
36.4%
Operating Margin
-21.8%
Net Margin
-18.8%
YoY Growth
1.2%
EPS
$-0.82
Sunshine Biopharma Inc. Q2 FY2025 Financial Summary
Sunshine Biopharma Inc. reported revenue of $9.4M (up 1.2% YoY) for Q2 FY2025, with a net profit of $-1.8M (down 258.3% YoY) (-18.8% margin). Cost of goods sold was $6.0M, operating expenses totaled $5.5M.
Key Financial Metrics
| Total Revenue | $9.4M |
|---|---|
| Net Profit | $-1.8M |
| Gross Margin | 36.4% |
| Operating Margin | -21.8% |
| Report Period | Q2 FY2025 |
Sunshine Biopharma Inc. Annual Revenue by Year
Sunshine Biopharma Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $36.3M).
| Year | Annual Revenue |
|---|---|
| 2025 | $36.3M |
| 2024 | $34.9M |
| 2023 | $24.1M |
| 2022 | $4.3M |
Sunshine Biopharma Inc. Quarterly Revenue & Net Profit History
Sunshine Biopharma Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $8.6M | -10.6% | $-2.1M | -25.0% |
| Q3 FY2025 | $9.4M | +11.6% | $-883.8K | -9.4% |
| Q2 FY2025 | $9.4M | +1.2% | $-1.8M | -18.8% |
| Q1 FY2025 | $8.9M | +18.0% | $-1.2M | -13.3% |
| Q4 FY2024 | $9.6M | +24.9% | $-2.2M | -22.5% |
| Q3 FY2024 | $8.4M | +41.6% | $-1.2M | -14.2% |
| Q2 FY2024 | $9.3M | +67.3% | $-494.3K | -5.3% |
| Q1 FY2024 | $7.5M | +54.1% | $-1.3M | -17.0% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $7.5M | $9.3M | $8.4M | $9.6M | $8.9M | $9.4M | $9.4M | $8.6M |
| YoY Growth | 54.1% | 67.3% | 41.6% | 24.9% | 18.0% | 1.2% | 11.6% | -10.6% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $31.9M | $29.3M | $30.1M | $30.6M | $29.2M | $32.0M | $31.5M | $30.1M |
| Liabilities | $7.1M | $5.8M | $5.0M | $7.1M | $6.5M | $6.3M | $7.3M | $7.0M |
| Equity | $24.8M | $23.5M | $25.0M | $23.5M | $22.7M | $25.7M | $24.2M | $23.0M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-3.2M | $-4.6M | $-1.4M | $-3.4M | $-1.7M | $-1.3M | $-727800 | $-1.6M |